Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
Alexandre B CavalcantiFernando Godinho ZampieriRegis Goulart RosaLuciano C P AzevedoViviane C VeigaAlvaro AvezumLucas P DamianiAline MarcadentiLetícia Kawano-DouradoThiago LisboaDebora L M JunqueiraPedro G M de Barros E SilvaLucas TramujasErlon O Abreu-SilvaLigia N LaranjeiraAline T SoaresLeandro S EcheniqueAdriano J PereiraFlávio G R FreitasOtávio C E GebaraVicente C S DantasRemo H M FurtadoEveline P MilanNicole A GolinFábio F CardosoIsrael S MaiaConrado R Hoffmann FilhoAdrian P M KormannRoberto B AmazonasMonalisa F Bocchi de OliveiraAry Serpa-NetoMaicon FalavignaRenato D LopesFlávia R MachadoOtavio Berwangernull nullPublished in: The New England journal of medicine (2020)
Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care. (Funded by the Coalition Covid-19 Brazil and EMS Pharma; ClinicalTrials.gov number, NCT04322123.).